Combined transfer of human VEGF165 and HGF genes renders potent angiogenic effect in ischemic skeletal muscle

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Makarevich, Pavel ^a,b   Tsokolaeva, Zoya ^a   Shevelev, Alexander ^a,c   Rybalkin, Igor ^a,c   Shevchenko, Evgeny ^a   Beloglazova, Irina ^a   Vlasik, Tatyana ^a,c   Tkachuk, Vsevolod ^b   Parfyonova, Yelena ^a,b  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^b LOMONOSOV MOSCOW STATE UNIVERSITY   (Russian Federation)

^c MonA LLC   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLASMID VECTOR; RECOMBINANT GROWTH FACTOR; RECOMBINANT SCATTER FACTOR; RECOMBINANT VASCULOTROPIN 165; SCATTER FACTOR; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG; VASCULOTROPIN 165;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL CULTURE; CODON; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFECT; DRUG POTENCY; ELECTROPORATION; EMBRYO; EX VIVO GENE TRANSFER; EXPLANT; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; LEG ISCHEMIA; MALE; MONOTHERAPY; MOUSE; MUSCLE PERFUSION; NONHUMAN; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TISSUE HOMOGENATE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEK293 CELLS; HEPATOCYTE GROWTH FACTOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; NEOVASCULARIZATION, PATHOLOGIC; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862201467     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038776     Document Type: Article

References (40)

1. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, et al. (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348: 370-374.
2. Shigematsu H, Yasuda K, Sasajima T, Takano T, Miyata T, et al. (2011) Transfection of human HGF plasmid DNA improves limb salvage in Buerger's disease patients with critical limb ischemia. Int Angiol 30: 140-149.
3. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visona A, et al. (2008) Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 16: 972-978.
4. Gupta R, Losordo DW, (2010) Challenges in the translation of cardiovascular cell therapy. J Nucl Med 51: 122S-127S.
5. Gupta R, Tongers J, Losordo DW, (2009) Human studies of angiogenic gene therapy. Circ Res 105: 724-736.
6. Henry TD, Hirsch AT, Goldman J, Wang YL, Lips DL, et al. (2011) Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Ther 18: 788-794.
7. Shimamura M, Morishita R, (2011) Naked plasmid DNA for gene therapy. Curr Gene Ther 11.
8. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, et al. (2011) Clinical applications of DNA vaccines: current progress. Clin Infect Dis 53: 296-302.
9. Wolff JA, Budker V, (2005) The mechanism of naked DNA uptake and expression. Adv Genet 54: 3-20.
10. Wells DJ, (2010) Electroporation and ultrasound enhanced non-viral gene delivery in vitro and in vivo. Cell Biol Toxicol 26: 21-28.
11. Patil SD, Rhodes DG, Burgess DJ, (2005) DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J 7: E61-77.
12. Arsic N, Zentilin L, Zacchigna S, Santoro D, Stanta G, et al. (2003) Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther 7: 450-459.
13. Li J, Wei Y, Liu K, Yuan C, Tang Y, et al. (2010) Synergistic effects of FGF-2 and PDGF-BB on angiogenesis and muscle regeneration in rabbit hindlimb ischemia model. Microvasc Res 80: 10-17.
14. Traktuev DO, Tsokolaeva ZI, Shevelev AA, Talitskiy KA, Stepanova VV, et al. (2007) Urokinase gene transfer augments angiogenesis in ischemic skeletal and myocardial muscle. Mol Ther 15: 1939-1946.
15. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, et al. (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119: 629-641.
16. Rosen EM, Lamszus K, Laterra J, Polverini PJ, Rubin JS, et al. (1997) HGF/SF in angiogenesis. Ciba Found Symp 212: 215-226; discussion 227-219.
17. Ferrara N, (1999) Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 56: 794-814.
18. Zhang YW, Su Y, Volpert OV, Vande Woude GF, (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 100: 12718-12723.
19. Wojta J, Kaun C, Breuss JM, Koshelnick Y, Beckmann R, et al. (1999) Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest 79: 427-438.
20. Xin X, Yang S, Ingle G, Zlot C, Rangell L, et al. (2001) Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 158: 1111-1120.
21. Van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, et al. (1998) Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97: 381-390.
22. Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R, et al. (2003) Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23: 69-75.
23. Makarevich PI, Shevelev AY, Rybalkin IN, Kashirina NM, Lipatova NM, et al. (2010) Novel plasmid constructs with angiogenic growth factors genes - human VEGF, HGF and angiopoietin-1 for therapeutic angiogenesis. Cell Transpl Cell Engin V: 47-52 [Article in Russian].
24. Antonova OA, Loktionova SA, Romanov YA, Shustova ON, Khachikian MV, et al. (2009) Activation and damage of endothelial cells upon hypoxia/reoxygenation. Effect of extracellular pH. Biochemistry (Mosc) 74: 605-612.
25. Jang HS, Kim HJ, Kim JM, Lee YS, Kim KL, et al. (2004) A novel ex vivo angiogenesis assay based on electroporation-mediated delivery of naked plasmid DNA to skeletal muscle. Mol Ther 9: 464-474.
26. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, et al. (1998) Mouse model of angiogenesis. Am J Pathol 152: 1667-1679.
27. Schertzer JD, Lynch GS, (2008) Plasmid-based gene transfer in mouse skeletal muscle by electroporation. Methods Mol Biol 433: 115-125.
28. Barreau C, Paillard L, Osborne HB, (2005) AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res 33: 7138-7150.
29. Efimenko A, Starostina E, Kalinina N, Stolzing A, (2011) Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning. J Transl Med 9: 10.
30. Mughal NA, Russell DA, Ponnambalam S, Homer-Vanniasinkam S, (2012) Gene therapy in the treatment of peripheral arterial disease. Br J Surg 99: 6-15.
31. Sedighiani F, Nikol S, (2011) Gene therapy in vascular disease. Surgeon 9: 326-335.
32. Gu Y, Zhang J, Guo L, Cui S, Li X, et al. (2011) A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia. J Gene Med 13: 602-610.
33. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, et al. (2008) Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 118: 58-65.
34. Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, et al. (2011) Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 377: 1929-1937.
35. Ferrara N, (2009) Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 29: 789-791.
36. Ferrara N, (2009) VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 20: 158-163.
37. Kowanetz M, Ferrara N, (2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12: 5018-5022.
38. Gerritsen ME, (2005) HGF and VEGF: a dynamic duo. Circ Res 96: 272-273.
39. Min JK, Lee YM, Kim JH, Kim YM, Kim SW, et al. (2005) Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res 96: 300-307.
40. Korpisalo P, Karvinen H, Rissanen TT, Kilpijoki J, Marjomaki V, et al. (2008) Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels. Circ Res 103: 1092-1099.